Multiple infliximab biosimilar switches: results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111 in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry
Poster published in 2021 by
Hafsah Nabi,
Bente Glintborg,
Anne Gitte Loft,
Oliver Hendricks,
Jens Kristian Pedersen 
,
Søren Andreas Just,
R. Ahmed,
K. Danebod,
Heidi Munk ,
Ada Colic,
Asta Linauskas,
D. Jensen,
L. Christensen,
N. Manilo,
Niels Lomborg
and other authors.
,
Søren Andreas Just,
R. Ahmed,
K. Danebod,
Heidi Munk ,
Ada Colic,
Asta Linauskas,
D. Jensen,
L. Christensen,
N. Manilo,
Niels Lomborg
and other authors.
